Clinical Trial Update: Study Evaluating InductOs in Diaphyseal Tibia Fractures [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating InductOs for diaphyseal tibia fractures has completed with results posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diaphyseal Fracture of Tibia
• Fracture of Tibia

Drugs mentioned

• InductOs (bone morphogenetic protein-2 (rhBMP-2))

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Tibial Fractures | Phase 4 | Status: COMPLETED | Results posted: 2009-09-07